Price$7.50-3.93 (-34.38%)
2026-03-052026-06-08
News · 26 weeks27-60%
2025-12-142026-06-07
Mix1890d
- SEC Filings8(44%)
- Earnings4(22%)
- Other4(22%)
- Leadership1(6%)
- Insider1(6%)
Latest news
25 items- PRDario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health PlatformData from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 monthsNEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA
- PRDario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible LivesExpansion driven by highly successful partnership based on Dario's consistent ability to engage members and deliver scalable value across cardiometabolic conditions NEW YORK, May 26, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that its largest network partner to date, Solera Health, a leading digital health network connecting curated solutions to employers, health plans and other payers, has broadened Dario's digital health offerings on its platform to include an expanded hypertension program. Hypertension represents one of the largest unmet needs in healthcare, affecting nearly half of all
- PRDarioHealth Reports First Quarter 2026 Financial and Operating ResultsFirst quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks
- SECSEC Form 10-Q filed by DarioHealth Corp.10-Q - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form SD filed by DarioHealth Corp.SD - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 13th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Wednesday, May13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-80
- PRDario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative ResearchFindings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plansStatistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payersNEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, t
- INSIDERSEC Form 3 filed by new insider Palumbo John R3 - DarioHealth Corp. (0001533998) (Issuer)
- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- PRDario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial ScalingMr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors. The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye
- SECSEC Form 424B5 filed by DarioHealth Corp.424B5 - DarioHealth Corp. (0001533998) (Filer)
- SECDarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form EFFECT filed by DarioHealth Corp.EFFECT - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form S-8 filed by DarioHealth Corp.S-8 - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form S-3 filed by DarioHealth Corp.S-3 - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsFourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-
- SECSEC Form 10-K filed by DarioHealth Corp.10-K - DarioHealth Corp. (0001533998) (Filer)
- PRDarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb
- PRDario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital HealthFindings reinforce that engagement data provide clinical signals directly impacting ROIAnalysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curveNEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414
- PRDario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight ManagementAs oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DarioHealth Corp.SCHEDULE 13G/A - DarioHealth Corp. (0001533998) (Subject)
- SECDarioHealth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECDarioHealth Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DarioHealth Corp. (0001533998) (Filer)
- PRDario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based PlatformsGrowing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery NEW YORK, Jan. 21, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has surpassed 100 scientific studies, including peer-reviewed journal publications and peer-reviewed conference abstracts, marking a significant milestone in the Company's commitment to delivering rigorously validated outcomes for employers, health plans and their members. Reaching this thresh
- SECSEC Form EFFECT filed by DarioHealth Corp.EFFECT - DarioHealth Corp. (0001533998) (Filer)
DRIO FAQ
6 questionsWhat does DarioHealth Corp. do?
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was...Where does DRIO stock trade?
DarioHealth Corp. (DRIO) is listed on NASDAQ.What sector and industry is DRIO in?
DarioHealth Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRIO?
DarioHealth Corp. has had 4 recent analyst actions on file. The most recent action was from TD Cowen: Hold with a $100.00 price target on 2025-01-29.What companies are similar to DRIO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DRIO side-by-side with any of them on Quantisnow.How can I track DRIO on Quantisnow?
Quantisnow aggregates DarioHealth Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRIO to receive live email and push alerts on every new disclosure.